26568-26-3

Basic information

• Product Name: trans-[2-(4-Fluorophenyl)cyclopropyl]aMine Hydrochloride
• Synonyms: trans-[2-(4-Fluorophenyl)cyclopropyl]aMine Hydrochloride
• CAS NO: 26568-26-3
• Molecular Formula: C9H12ClN
• Molecular Weight: 169.65128
• Product Categories: Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 26568-26-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: trans-[2-(4-Fluorophenyl)cyclopropyl]aMine Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: trans-[2-(4-Fluorophenyl)cyclopropyl]aMine Hydrochloride(26568-26-3)
• EPA Substance Registry System: trans-[2-(4-Fluorophenyl)cyclopropyl]aMine Hydrochloride(26568-26-3)

Safety Data

• Hazardous Substances Data: 26568-26-3(Hazardous Substances Data)

Usage

Description

trans-[2-(4-Fluorophenyl)cyclopropyl]aMine Hydrochloride, also known as F588535, is a synthetic intermediate that plays a crucial role in the development of thiazolinone 4-monosubstituted quinolines. These quinolines act as CDK1-Cyclin B inhibitors, which are essential in the fight against cancer.

Uses

Used in Pharmaceutical Industry:
trans-[2-(4-Fluorophenyl)cyclopropyl]aMine Hydrochloride is used as a synthetic intermediate for the preparation of thiazolinone 4-monosubstituted quinolines. These quinolines serve as CDK1-Cyclin B inhibitors, which are vital in the development of anti-cancer agents. The compound's role in inhibiting CDK1-Cyclin B interactions makes it a promising candidate for cancer treatment, particularly in targeting the cell cycle and preventing uncontrolled cell proliferation.

Upstream product

• 113516-71-5 (1R,2S)-2-(4-fluorophenyl)cyclopropan-1-amine 
• 210422-66-5 4-fluorobenzaldehyde p-toluenesulfonylhydrazone 
• 459-57-4 4-fluorobenzaldehyde 
• 107633-40-9 4-fluorophenyl benzaldehyde-tosylhydrazone sodium salt 
• 161711-27-9 (1R,2R)-2-(4-fluorophenyl)cyclopropanecarboxylic acid 
• 405-99-2 para-fluorostyrene 
• 1314323-96-0 (1R,2S)-tert-butyl 2-(4-fluorophenyl)cyclopropylcarbamate 
• 879324-65-9 [2-(4-fluoro-phenyl)-cyclopropyl]-carbamic acid tert-butyl ester 
• 893751-08-1 trans-methyl 2-(4-fluorophenyl)cyclopropanecarboxylate 
• 96426-60-7 methyl (2E)-3-(4-fluorophenyl)-2-propenoate 
• 352-34-1 4-fluoro-1-iodobenzene 
• 515179-19-8 (±)-trans-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid 

Relevant articles and documents

CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

NOVEL COMPOUNDS

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.

Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors

Asymmetric cyclopropanation of styrenes by tert-butyl diazoacetate followed by ester hydrolysis and Curtius rearrangement gave a series of tranylcypromine analogues as single enantiomers. The o,- m- and p-bromo analogues were all more active than tranylcypromine in a LSD1 enzyme assay. The m- and p-bromo analogues were micromolar growth inhibitors of the LNCaP prostate cancer cell line as were the corresponding biphenyl analogues prepared from the bromide by Suzuki crosscoupling.